Long-Term GLP-1 Use May Slow Medical Cost Growth
Sustained use of GLP-1 medications is associated with slower medical cost growth over time, according to new findings from Aon. The analysis examined claims data from more than 190,000 GLP-1 users between 2022 and 2025 and found that consistent use—particularly with high adherence—was linked to lower medical cost growth compared to non-users. The research suggests cost trends improve the longer patients remain on therapy, with the strongest impact seen among individuals using GLP-1s for diabetes…
Read Full Article